Other Science

LYNPARZA® (olaparib) plus abiraterone approved in the US for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer

Retrieved on:

Thursday, June 1, 2023

Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science

In PROpel, the LYNPARZA combination improved radiographic progression-free survival and overall survival for the subgroup of patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Key Points:

In PROpel, the LYNPARZA combination improved radiographic progression-free survival and overall survival for the subgroup of patients with BRCA-mutated metastatic castration-resistant prostate cancer.
In combination with abiraterone and prednisone or prednisolone (abi/pred) for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).
In China, LYNPARZA is approved for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as a 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer as well as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.

ReAlta Life Sciences Announces Proof of Mechanism Data from the Phase 1b Inhaled LPS Trial of RLS-0071, Demonstrating Powerful Inhibition of Lung Neutrophils and Inflammatory Cytokines

Retrieved on:

Thursday, June 1, 2023

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced exciting new proof-of-mechanism data from the company’s Phase 1b Inhaled LPS clinical trial of RLS-0071 presented at the American Thoracic Society International Conference on May 23, 2023.

Key Points:

ReAlta Life Sciences (“ReAlta”), Inc., a company addressing life-threatening rare diseases through harnessing the power of the immune system, today announced exciting new proof-of-mechanism data from the company’s Phase 1b Inhaled LPS clinical trial of RLS-0071 presented at the American Thoracic Society International Conference on May 23, 2023.
RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide in development as a treatment for HIE and other rare diseases.
Blood and sputum were collected for analysis at 6-hour and 24-hour timepoints.
Based on the data from the Phase 1b Inhaled LPS trial, ReAlta plans further development in neutrophil-mediated pulmonary disease indications.

Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

Retrieved on:

Thursday, June 1, 2023

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.

Key Points:

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations.
The new data release indicates that ctDNA shows promise as an early endpoint to support drug development and regulatory decision-making.
“We are thrilled to partner with our colleagues in industry, academia, government and Friends of Cancer Research in contributing to the new data analysis on ctDNA and outcomes that will be released at the ASCO 2023 Annual Meeting,” said Gary Pestano, Chief Development Officer of Biodesix.
These analyses evaluated healthcare resource utilization (HCRU) and healthcare costs in patients with non-small cell lung cancer (NSCLC) classified by the test.

Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)

Retrieved on:

Thursday, June 1, 2023

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.

Key Points:

NMOSD is most notably associated with acute attacks, which can cause irreversible damage to the optic nerve, spinal cord, brain and brain stem.
Disease management goals are focused on prevention of attacks, as well as understanding and tracking biomarkers that could signal these attacks.
The strong link suggests that higher sNfL levels may be associated with more severe attacks and increased risk of residual disability.
Compared with placebo, UPLIZNA was shown to hinder biomarker elevation during attacks while reducing biomarker levels over time in the absence of attacks.

ArteraAI Presents New Data Validating AI-Derived Predictive Biomarker at 2023 ASCO Annual Meeting

Retrieved on:

Thursday, June 1, 2023

Research, Technology, Other Technology, Biometrics, General Health, Health, Science, Oncology, Artificial Intelligence, Other Science, ASCO, Duke University, AI, Radiation, ADT, MD, Patient, Medical imaging, Medicine

ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting.

Key Points:

ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting.
The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation therapy (ADT) in men with localized high-risk prostate cancer.
In patients with high-risk localized prostate cancer, ADT is considered a cornerstone of treatment, along with radiotherapy.
To help guide a treatment plan that will maximize benefits and minimize risks, predictive biomarkers are needed.

NTT Demonstrates ‘World’s First’ Breakthroughs in Human Information Presentation and Processing

Retrieved on:

Thursday, June 1, 2023

NTT Corporation (President and CEO: Akira Shimada, "NTT") has accomplished significant breakthroughs in the areas of information and human sciences, with the demonstration of multiple findings categorized as the first of their kind in the world.

Key Points:

NTT Corporation (President and CEO: Akira Shimada, "NTT") has accomplished significant breakthroughs in the areas of information and human sciences, with the demonstration of multiple findings categorized as the first of their kind in the world.
(Photo: Business Wire)
These developments advance theories such as communication in the form of dynamic shape presentation using pin-based shape-changing display, speech recognition and extraction of information from speech information.
The research is being displayed at the NTT Communication Science Laboratories Open House 2023 on June 1-2, 2023, at the NTT West Quintbridge in Osaka.
For more information, please visit: https://arxiv.org/abs/2207.11964
In a new study, NTT researchers investigated the relationship between auditory attention situations and fine eye movements.

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists

Retrieved on:

Thursday, June 1, 2023

Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Cancer, Immune system, Toll, Therapy, Toll-like receptor 7, Patient, Pharmaceutical industry, Fine chemical, Eikon

As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).

Key Points:

As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).
“We have made great progress in the field of TLR7/8 agonists and advanced our molecules to industry leading positions,” said Walter Lau, Ph.D., Chief Executive Officer of Seven and Eight Biopharmaceuticals.
“We are delighted to have the Eikon team continue the clinical development and ultimate commercialization of these molecules.
“In addition, encouraging clinical responses have been seen in both mono- and combination therapy in multiple heavily pre-treated tumor types.

PTP Announces Significant Investment by 424 Capital

Retrieved on:

Thursday, June 1, 2023

PTP, a leading cloud consulting and managed services firm specializing in the life sciences industry, is pleased to announce it has closed a significant investment by 424 Capital.

Key Points:

PTP, a leading cloud consulting and managed services firm specializing in the life sciences industry, is pleased to announce it has closed a significant investment by 424 Capital.
With 424 Capital’s investment, PTP will increase the breadth and depth of services that empower companies in the therapeutics space to get treatments to market.
"We are excited to close this investment with 424 Capital," said Ethan Simmons, Managing Partner of PTP.
"The power of PTP’s cloud and managed services portfolio combined with the additional business-growth expertise of 424 Capital will enable PTP to provide valuable services and cloud solutions to a greater number of life sciences clients and net-new markets.”
Brennan Mulcahey, Managing Partner of 424 Capital, expressed similar enthusiasm for the investment: "424 Capital seeks to partner with leading organizations that have the opportunity to shape the future of their industry.

Pixxel Raises $36 Million in Series B Funding to Advance Hyperspectral Satellite Constellation and Data Platform

Retrieved on:

Thursday, June 1, 2023

Professional Services, Philanthropy, Other Natural Resources, Mining, Minerals, Forest Products, Other Philanthropy, Other Science, Construction & Property, Agriculture, Research, Natural Resources, Other Defense, Other Manufacturing, Contracts, Transportation, Travel, Engineering, Other Transport, Aerospace, Maritime, Manufacturing, Science, Transport, Other Technology, Telecommunications, Networks, Internet, Hardware, Electronic Design Automation, Data Management, Nuclear, Technology, Defense, White House, Federal Government, Environment, State, Local, Public Policy, Other Policy Issues, Urban Planning, Elections, Campaigns, Government, Satellite, Other Energy, Utilities, Nanotechnology, Oil, Gas, Coal, Alternative Energy, Energy, Supply Chain Management, Logistics, Mobile, Wireless, Retail, Finance, Consulting, Aurora, Water pollution, Orbit, Pathfinder, Organization, Growth, ESG, Commercial, Health, Risk management, Communications satellite, Speed of light

The new funds will advance Pixxel’s mission to build the world’s first and highest-resolution hyperspectral satellite constellation, delivering actionable climate insights on a planetary scale.

Key Points:

The new funds will advance Pixxel’s mission to build the world’s first and highest-resolution hyperspectral satellite constellation, delivering actionable climate insights on a planetary scale.
It will also help further the development of Aurora: Pixxel’s AI-powered analytics platform to make hyperspectral analysis accessible for everyone.
“At Pixxel, we believe that the future of our planet lies in our ability to monitor and protect its health precisely.
The hyperspectral constellation and advanced data analytics platform will provide up to 10x more information compared to today’s multispectral satellites in space and increase the spectral resolution available by 50x.

Submissions Now Open for $1 Million USD Seeding The Future Global Food System Challenge

Retrieved on:

Thursday, June 1, 2023

Submissions for the third annual Seeding The Future Global Food System Challenge are now open.

Key Points:

Submissions for the third annual Seeding The Future Global Food System Challenge are now open.
“Transformational change is urgently needed to create food systems that improve the health of people and the planet.
We are excited and look forward to the highly impactful entries we receive for this year’s Challenge,” said Bernhard van Lengerich, founder of Seeding The Future Foundation.
iDE (Growth Grant): “iDE's recognition as a winner of the Seeding The Future Global Food System Challenge has brought significant attention to the organization and its efforts to address food system challenges.